Fibrinogen from human plasma
SIGMA/F3879 - 50-70% protein (≥80% of protein is clottable)
Synonym: Factor I
CAS Number: 9001-32-5
EC Number: 232-598-6
MDL Number: MFCD00131060
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F3879-5G
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F3879-100MG
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F3879-250MG
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F3879-1G
| biological source | human plasma |
| concentration | 50-70% protein (biuret) |
| form | powder |
| mol wt | α-chain 63.5 kDa |
| β-chain 56 kDa | |
| γ chain 47 kDa (about 4% carbohydrate content) | |
| soluble dimer 340 kDa | |
| quality | 50-70% protein (≥80% of protein is clottable) |
| Quality Level | 300  |
| solubility | 0.9% NaCl: soluble 10 mg/mL |
| storage temp. | −20°C |
| technique(s) | ELISA: suitable |
| UniProt accession no. | P02671  |
| P02675 |
|
| P02679 |
| Analysis Note: | Protein determined by biuret |
| Application: | Fibrinogen was used in the induction of release of TNF-like cytotoxic factor from murine macrophages. It was used for fabrication of fibrin scaffolds with controlled microscale architecture by a two-photon polymerization-micromoldi Fibrinogen was also used in the development of a fibrinogen-specific sandwich enzyme-linked immunosorbent assay microarray assay for distinguishing between blood plasma and serum samples. Fibrinogen from human plasma has been used- • for the production of fibrin hydrogels • for the preparation of fibrin-MSCs (mesenchymal stem cells)-cartilage constructs • for analyzing the protein repellent properties of PFDA-co-DEGDME (diethyleneglycol dimethyl ether) surface using Quartz crystal microbalance (QCM) |
| Biochem/physiol Actions: | Acute phase protein that is part of the coagulation cascade of proteins. |
| Biochem/physiol Actions: | Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source. |
| Disclaimer: | RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization. |
| Features and Benefits: | Source material has tested negative for HIV and HBsAg. |
| General description: | Fibrinogen, or Factor I, is a blood protein that is involved in clotting and is converted to fibrin by thrombin. Fibrinogen has an approximate molecular weight of 340 kDa |
| Packaging: | 1, 5 g in poly bottle |
| Packaging: | 100, 250 mg in poly bottle |
| Physical form: | Lyophilized powder containing ~15% sodium citrate and ~25% sodium chloride. |
| Preparation Note: | The optimal way to solubilize fibrinogen is to layer it on top of warm (37 ºC) saline, as fibrinogen will not dissolve in water. The saline concentration can be in the range of 0.85-0.9%. The fibrinogen-saline solution can be gently agitated, but it must not be vortexed. The fibrinogen will slowly dissolve to give a hazy solution. Fibrinogen may be sterile-filtered, but may not go through a 0.1 μ filter. A 0.2 μ filter is suggested, with positive pressure using a syringe and "button" filter. Vacuum filtration should not be used, since this will lead to breakdown of the molecule during the filtration. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |